Compare Inovio Pharmaceuticals Inc (INO) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Sibanye Stillwater Ltd trades at $10 (market cap $6.88B). The key difference: Sibanye Stillwater Ltd is far larger — about 61.3× Inovio Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Sibanye Stillwater Ltd for 51 Days on average.
| INO | SBSW | |
|---|---|---|
Market Cap | $112.19M | $6.88B |
Volume | 3,201,278 | 4,474,536 |
Sector | Health | Basic Materials |
52-Week High | $2.65 | $21.12 |
52-Week Low | $0.66 | $8.00 |
Typical Hold Time | 43 Days | 51 Days |
Enterprise Value | $83.51M | $7.78B |
Dividend Yield | — | 8.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Sibanye Stillwater (SBSW) trades at $9.91, up 2.38% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong revenue growth to $129.68 billion in 2025 with improving margins, though net income remains negative. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26 expected, indicating operational momentum. Analyst sentiment is cautiously optimistic with a Moderate Buy consensus and $14.25 price target representing 44% upside potential.
The stock presents a turnaround opportunity with attractive valuation metrics (P/E 8.12, P/S 0.7) and strong cash flow generation, but faces risks from volatile commodity prices and persistent negative earnings. Institutional ownership is growing with recent 81.4% position increase by MAC Alpha Capital. The key catalyst remains sustained profitability improvement and execution of the 2027-2028 growth roadmap.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
